Bioniq secures $15m Series B funding from HV Capital and Unbound to drive international expansion.
The Series B round was led by HV Capital and Unbound, with participation from Cristiano Ronaldo, to fund global expansion.
Bioniq offers personalised nutritional supplements driven by blood biomarker data and artificial intelligence. The firm serves customers across seventy countries globally.
Bioniq has secured $15m in a Series B funding round led by HV Capital and Unbound, alongside a significant investment from soccer icon Cristiano Ronaldo. The fresh capital will be deployed to accelerate international expansion across the US, Europe, and the Middle East, while driving further product development. The company combines advanced blood biomarker analysis with a patent-pending algorithm to generate customized daily supplements for users in over 70 countries.
From the founder
"Backing Bioniq goes beyond just an investment opportunity for me—it’s about aligning with a shared vision for health, performance, and longevity. I have been using their products myself for almost three years. With their personalized health approach, I believe Bioniq has the potential to transform how we care for our bodies and help people reach and maintain their peak performance for longer."
Cristiano Ronaldo
Shareholder and Investor at Bioniq
Investor perspective
"The personalized health and nutrition market is expansive, and Bioniq is leading the way with its innovative approach to personalization."
David Kuczek
General Partner, HV Capital
Use of funds
- 01Expand into international markets
- 02Continue product development
Investors
Categories
About the company
Bioniq
Bioniq provides personalised nutritional supplements formulated from blood biomarker data.